Active trials in MGUS
| Title . | Intervention . | Status . | URL . |
|---|---|---|---|
| Registry and prospective studies | |||
| Predicting progression of developing myeloma in a high-risk screened population (PROMISE) | Recruiting | https://clinicaltrials.gov/show/NCT03689595 | |
| Collection of specimens and clinical data to create a bio-repository for multiple myeloma | Recruiting | https://clinicaltrials.gov/show/NCT03616483 | |
| Iceland screens, treats or prevents multiple myeloma | Active, not recruiting | https://clinicaltrials.gov/show/NCT03327597 | |
| Unravel MGUS (monoclonal gammopathy of unknown significance) | Recruiting | https://clinicaltrials.gov/show/NCT02933021 | |
| Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies | Recruiting | https://clinicaltrials.gov/show/NCT02726750 | |
| Study of MGUS, smoldering myeloma, early MDS and CLL to assess molecular events of progression and clinical outcome | Recruiting | https://clinicaltrials.gov/show/NCT02269592 | |
| A prospective study of circulating multiple myeloma cells as a biomarker of progression in myeloma precursor states (MGUS and SMM) | Active, not recruiting | https://clinicaltrials.gov/show/NCT01958528 | |
| A diagnostic screening trial seeking amyloidosis very early (for patients with LC MGUS and SMM) | Recruiting | https://clinicaltrials.gov/ct2/show/NCT02741999 | |
| Studies with interventions to prevent progression of MGUS to MM | |||
| Phase II study of the CD38 antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma | Daratumumab | Recruiting | https://clinicaltrials.gov/show/NCT03236428 |
| Dendritic cell DKK1 vaccine for monoclonal gammopathy and stable or smoldering myeloma | DKK1 vaccine | Not yet recruiting | https://clinicaltrials.gov/show/NCT03591614 |
| Antigen-lipid-driven monoclonal gammopathies targeting epicardial fat | Liraglutide | Not yet recruiting | https://clinicaltrials.gov/show/NCT02920190 |
| Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma | Green tea extract | Terminated | https://clinicaltrials.gov/show/NCT00942422 |
| Rituximab in treating patients with peripheral neuropathy caused by monoclonal gammopathy of undetermined significance | Rituximab | Terminated | https://clinicaltrials.gov/show/NCT00588822 |
| RIMAG study: trial of rituximab versus placebo in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy | Rituximab | Completed | https://clinicaltrials.gov/show/NCT00259974 |
| Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma | Celecoxib | Completed | https://clinicaltrials.gov/show/NCT00099047 |
| Title . | Intervention . | Status . | URL . |
|---|---|---|---|
| Registry and prospective studies | |||
| Predicting progression of developing myeloma in a high-risk screened population (PROMISE) | Recruiting | https://clinicaltrials.gov/show/NCT03689595 | |
| Collection of specimens and clinical data to create a bio-repository for multiple myeloma | Recruiting | https://clinicaltrials.gov/show/NCT03616483 | |
| Iceland screens, treats or prevents multiple myeloma | Active, not recruiting | https://clinicaltrials.gov/show/NCT03327597 | |
| Unravel MGUS (monoclonal gammopathy of unknown significance) | Recruiting | https://clinicaltrials.gov/show/NCT02933021 | |
| Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies | Recruiting | https://clinicaltrials.gov/show/NCT02726750 | |
| Study of MGUS, smoldering myeloma, early MDS and CLL to assess molecular events of progression and clinical outcome | Recruiting | https://clinicaltrials.gov/show/NCT02269592 | |
| A prospective study of circulating multiple myeloma cells as a biomarker of progression in myeloma precursor states (MGUS and SMM) | Active, not recruiting | https://clinicaltrials.gov/show/NCT01958528 | |
| A diagnostic screening trial seeking amyloidosis very early (for patients with LC MGUS and SMM) | Recruiting | https://clinicaltrials.gov/ct2/show/NCT02741999 | |
| Studies with interventions to prevent progression of MGUS to MM | |||
| Phase II study of the CD38 antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma | Daratumumab | Recruiting | https://clinicaltrials.gov/show/NCT03236428 |
| Dendritic cell DKK1 vaccine for monoclonal gammopathy and stable or smoldering myeloma | DKK1 vaccine | Not yet recruiting | https://clinicaltrials.gov/show/NCT03591614 |
| Antigen-lipid-driven monoclonal gammopathies targeting epicardial fat | Liraglutide | Not yet recruiting | https://clinicaltrials.gov/show/NCT02920190 |
| Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma | Green tea extract | Terminated | https://clinicaltrials.gov/show/NCT00942422 |
| Rituximab in treating patients with peripheral neuropathy caused by monoclonal gammopathy of undetermined significance | Rituximab | Terminated | https://clinicaltrials.gov/show/NCT00588822 |
| RIMAG study: trial of rituximab versus placebo in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy | Rituximab | Completed | https://clinicaltrials.gov/show/NCT00259974 |
| Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma | Celecoxib | Completed | https://clinicaltrials.gov/show/NCT00099047 |
CLL, chronic lymphocytic leukemia; LC-MGUS, light-chain MGUS; MDS, myelodysplastic syndrome; RIMAG, Rituximab vs Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy.